Comparative Pharmacology
Head-to-head clinical analysis: NORPRAMIN versus PAMELOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPRAMIN versus PAMELOR.
NORPRAMIN vs PAMELOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norpramin (desipramine) is a tricyclic antidepressant (TCA) that primarily inhibits the reuptake of norepinephrine, and to a lesser extent serotonin, at the presynaptic neuronal membrane, thereby increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha1-adrenergic blocking properties.
Nortriptyline, the active ingredient, is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their availability in the synaptic cleft.
25 mg orally three times daily; may increase gradually to 150 mg/day in divided doses. Maximum 200 mg/day.
25-150 mg orally per day, typically as a single daily dose at bedtime or in divided doses; start at 25 mg 1-3 times daily and titrate gradually. Maximum 150 mg/day.
None Documented
None Documented
Terminal half-life: 18-34 hours (mean ~27 hours); clinical context: supports once-daily dosing, but steady-state requires 5-7 days.
Mean terminal elimination half-life is 18-24 hours (range 13-40 hours) in adults; prolonged in elderly and hepatic impairment (up to 60 hours). Steady-state achieved in 4-5 days.
Primarily renal (70%) as metabolites and unchanged drug; biliary/fecal (30%) as metabolites.
Primarily renal (approximately 70% as metabolites, 40-50% as glucuronide conjugates, 20-30% as free or conjugated nortriptyline; <5% unchanged), with 20-30% biliary/fecal elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant